Sectors
ARDX
Ardelyx, Inc.
3.78
2 x 3.62
2 x 6.45
bid
ask
-
0.03
0.79%
2 @ 07:39 PM
3.77 -0.01 (0.26%)
| Ytd | -35.16% | |
| 1y | -40.57% |
3.68
day range
3.81
3.68
52 week range
8.40
| Open | 3.80 | Prev Close | 3.81 | Low | 3.68 | High | 3.81 | Mkt Cap | 975.95M |
| Vol | 3.80M | Avg Vol | 4.22M | EPS | -0.23 | P/E | N/A | Forward P/E | 15.44 |
| Beta | 0.73 | Short Ratio | 8.72 | Inst. Own | 73.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 4.86 | 200-d Avg | 5.91 | 1yr Est | 12.90 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-10-29 | 2026-09 | -0.03 | N/A | N/A | N/A |
| 2026-08-06 | 2026-06 | -0.07 | -0.07 | N/A | -6.95% |
| 2026-04-30 | 2026-03 | -0.13 | -0.15 | -0.02 | -15.38% |
| 2026-02-19 | 2025-12 | 0.02 | 0.02 | N/A | N/A |
| 2025-10-30 | 2025-09 | -0.06 | 0 | 0.06 | 93.32% |
| 2025-08-04 | 2025-06 | -0.13 | -0.08 | 0.05 | 38.46% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-19 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-08-18 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-08-17 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2026-08-10 | Citigroup | Upgrade | Buy | Buy |
| 2026-08-07 | TD Cowen | Upgrade | Buy | Buy |
| 2026-08-07 | BTIG | Upgrade | Buy | Buy |
Profile
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-15 | BERTRAND WILLIAM C JR | Director | 329.51K | Stock Award(Grant) |
| 2026-05-20 | BISHOP JOHN E | Officer | 336.85K | Sale |
| 2026-05-20 | FOSTER ERIC DUANE | Officer | 417.97K | Sale |
| 2026-05-20 | KELLIHER MICHAEL | Officer | 357.42K | Sale |
| 2026-06-15 | MOTT DAVID M | Director | 3.35M | Stock Award(Grant) |
| 2026-07-14 | RAAB MICHAEL G | Chief Executive Officer | 1.70M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Blackrock Inc. | 23.50M | 91.43M | 9.43% |
| 2026-06-29 | Rubric Capital Management LP | 16.20M | 63.03M | 6.50% |
| 2026-06-29 | Millennium Management Llc | 13.90M | 54.07M | 5.58% |
| 2026-06-29 | State Street Corporation | 13.36M | 51.96M | 5.36% |
| 2026-06-29 | Vanguard Capital Management LLC | 10.47M | 40.73M | 4.20% |
| 2026-06-29 | Nomura Asset Management International Inc | 9.55M | 37.14M | 3.83% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 7.40M | 28.80M | 2.97% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 7.39M | 28.74M | 2.97% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 6.40M | 24.90M | 2.57% |
| 2026-05-30 | Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 6.27M | 24.37M | 2.51% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.70M | 10.51M | 1.08% |
| 2026-05-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 2.39M | 9.31M | 0.96% |
Split
| Split | Date |
|---|---|
| 4 : 1 | 2021-07-20 |